Appleman JR, Webber SE. Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer. In: 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer...
SAN DIEGO, November 6, 2019 – Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD. PRX034 is a novel orally bioavailable small...
Appleman JR, Webber SE. Discovery of a series of novel toll-like receptor 7 agonists for systemic immunotherapy of cancer. In: Proceedings of the American Association for Cancer Research AACR Annual Meeting; 2019 March 29-April 3, Atlanta, GA, Abstract 3262. To...
SAN DIEGO, April 1, 2019 – Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research...
We use cookies to improve your experience on the Primmune website. By continuing to use our site, you agree to our use of cookies. Learn More
